Skip to content

Study to test the safety and effectiveness of test product to provide various skin benefits in participants over 56 days of test product usage

A Clinical Study to Evaluate the Safety and Efficacy of the Test Product in Providing Various Skin Benefits. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089217
Enrollment
30
Registered
2025-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Serum UV drops: Apply at least two pumps of product and blend evenly over your face, neck and neckline in the morning. Use as the last step of your skincare routine, after your moisturi

Sponsors

Antonio Puig S.A
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female subjects in general good health. 2. Female subjects in the age group 20 to 65 years. 3. Female subjects with all skin types, with 50% of subjects having sensitive skin. 4. Female subjects with visible skin concerns such as dark spots, wrinkles, and uneven skin tone. 5.10 female subjects with sensitive eyes who regularly wear contact lenses. 6.Female subjects who are regular users of makeup.

Exclusion criteria

Exclusion criteria: 1. Subjects with known skin conditions that may impact the assessment. 2. Subjects with any other signs of significant local irritation or skin disease. 3. Subjects undergoing treatment of any skin condition on their face. 4. Subject having active skin diseases. 5. Subjects who have undergone facial treatments in past 4 weeks.

Design outcomes

Primary

MeasureTime frame
Evaluation of efficacy of test product in reducing signs of ageing. Assessment of the test products effectiveness in improving overall skin tone. Evaluation of efficacy of the test product for reduction in dark spots. Reduction in signs of ageing using Antera assessment. Reduction in dark spot intensity using Spectrophotometer. Evaluation of improvement in skin elasticity using Cutometer.Timepoint: Baseline, Day 28, Day 56.

Secondary

MeasureTime frame
1. Evaluation of Safety and tolerability of the test product through dermatological and ophthalmological assessments. 2. Assessment of prevention of dark spots through subject self assessment.Timepoint: Baseline, Day 28, Day 56.

Countries

India

Contacts

Public ContactSudhanthiran S

MS Clinical Research Pvt. Ltd

ritambhara@msclinical.com8040917253

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026